Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical ...